Roche breast cancer drug fails in Phase 2 following similar stumble by rival Sanofi

Experimental Roche drug giredestrant failed to meet the main goal of a Phase 2 study in advanced breast cancer. The disappointing results allow competitors to gain ground in the field of companies developing oral selective estrogen receptor degraders (SERDs), drugs that block a receptor key to driving breast cancer growth.

Related Keywords

New Haven ,Connecticut ,United States ,Switzerland ,Swiss ,Eli Lilly Loxo ,Pfizer ,Seragon Pharmaceuticals ,Astrazeneca ,Menarini Group ,Radius Health ,New York Based Zentalis ,Eli Lilly ,Loxo Oncology ,Weight Loss ,Obesity ,Verweight ,Diabetes ,Massachusetts ,Medical Devices ,Startups ,Healthcare Innovation ,Medcity News ,San Francisco ,Life Sciences ,Accelerator ,Rock Health ,Startup Advice ,Startup Funding ,Patient Monitoring System ,Otion Sensors ,Dc ,Healthcare It ,Washington ,Foodborne Pathogens ,Iagnostics Company ,Iagnostic Platforms ,Minimally Invasive Surgery ,Aser Surgery ,Cambridge ,Dealflow ,Hospitals ,Wellpoint ,Ealthways ,Ealth And Wellness ,Mployee Wellness Programs ,Investing ,Wellness ,Medtronic ,Hanghai Innovation Center ,China ,R D ,Mdt ,Minneapolis ,Minnesota ,Publics ,Twin Cities ,Ulcerative Colitis ,Abbott Labs ,Humira ,Doctors ,Pharmaceuticals ,Skin Disorders ,D Anderson Cancer Center ,Cancer ,Texas ,Renal Denervation ,St Jude Medical ,Stj ,Emr ,Hr ,Electronic Health Records ,Electronic Medical Records ,Certified Emr ,Ehr ,Advanced Cellular Technology ,Amyotrophic Lateral Sclerosis ,Embryonic Stem Cells ,Geron Corporation ,Lou Gehrigs Disease ,Macular Degeneration ,Regenerative Medicine ,Spinal Cord Damage ,Value Based Healthcare System ,Obamacare ,Ee For Service Model ,California ,Cleveland ,Health Insurance ,Insurance ,Ohio ,Pennsylvania ,Politics ,Cancer Treatment Options Library ,Aetna ,Pet ,Aet ,Health It ,Phi ,Philadelphia ,Breast Cancer ,Dancer ,Clinical Trials ,Giredestrant ,Oche ,Sanofi , ,